Anavex Life Sciences Corp. (AVXL) Stock Score, Valuation & Financial Research

Anavex Life Sciences Corp. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AVXL

Anavex Life Sciences Corp. does not currently have a complete Wall Street Score. The stored market price is USD 2.02. These figures are a research snapshot, not a buy or sell recommendation.

What Anavex Life Sciences Corp. does

Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.

Company business and revenue

Research reporting period: 2025-09-30. A research update is not a new financial filing.

How the company makes money

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research, development, and clinical testing of small-molecule drug candidates for central nervous system diseases, relying on capital raises and equity financing to fund its ongoing operations and drug development pipeline.

Products and services

The company is developing a pipeline of CNS-focused therapeutic candidates, most notably Blarcamesine (ANAVEX 2-73), which is being investigated for the treatment of Alzheimer's disease, Parkinson's disease, and Rett syndrome.

Brands and product families

Blarcamesine (ANAVEX 2-73) — Lead clinical-stage drug candidate for Alzheimer's and other CNS disorders. Source

Customer types

Clinical trial participants.

Suppliers, materials and equipment

Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct clinical trials and manage data. Source
Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract manufacturing organizations for the production of its drug candidates for clinical use. Source

Business strengths to evaluate

Proprietary pipeline of CNS-focused drug candidates Source
Application of precision medicine to CNS diseases Source

Business risks and research considerations

History of operating losses and expectation of future losses Source
Dependence on the success of a limited number of drug candidates Source
Risks associated with clinical trial outcomes and regulatory approval processes Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AVXL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 2.02
Market capitalization:: 187.2M (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -24.04M
Free cash flow:: USD -39.04M
Cash:: USD 118.33M
Total debt:: USD 0.00
EPS:: USD -0.26

What stands out

Free cash flow is USD -39.04M, negative for the stored period.
The balance sheet shows USD 118.33M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 118.33M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AVXL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can AVXL fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is AVXL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for AVXL to reach sustainable profitability?
What does the current missing revenue history warning mean for the reliability or interpretation of AVXL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research AVXL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.